# A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy W

Source: https://onco.cc/trials/nct07178717/  
OnCo record `nct07178717` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of bevacizumab (glioblastoma use) and encorafenib in colorectal cancer, run by Vall d'Hebron Institute of Oncology, not yet recruiting.

## Summary

A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations is a phase 2, interventional study registered as NCT07178717 by Vall d'Hebron Institute of Oncology, with a registry enrolment figure of 25 participants, started 2025-10 and due to reach its primary completion in 2028-02. Interventions recorded: Rechalange with bevacizumab + encorafenib. Conditions listed: Colo-rectal Cancer. Primary outcome: Progression free survival. Colorectal eligibility wording from the registry: "5 x ULN is allowed if direct (conjugated) ≤1". Sites: Spain. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: REFISH
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07178717
- Phase: 2
- Setting: A Phase 2, Single-Arm Study of Encorafenib Plus Cetuximab as Rechallenge Treatment of BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations: the RefIsh Trial
- Sponsor: Vall d'Hebron Institute of Oncology
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT07178717: https://clinicaltrials.gov/study/NCT07178717

## Connected records

- cancers: [BRAF V600E-mutant colorectal cancer](https://onco.cc/cancers/braf-v600e-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Encorafenib](https://onco.cc/drugs/encorafenib/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07178717.json